Headquartered in Thousand Oaks, CA Fiscal year ends December NASDAQ: ATRA atarabio.com
Atara Biotherapeutics is a T-cell immunotherapy company leveraging its allogeneic Epstein-Barr virus (EBV) T-cell platform to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions. The company's advanced T-cell platform does not require T-cell receptor or HLA gene editing and forms the basis of a diverse portfolio of investigational therapies targeting EBV as the root cause of certain diseases. Atara is the first company to receive regulatory approval of an allogeneic T-cell immunotherapy. Its lead product candidate, tabelecleucel (tab-cel, marketed as EBVALLO), targets EBV-positive post-transplant lymphoproliferative disease (PTLD). Following a Complete Response Letter from the FDA in January 2026, Atara's partner Pierre Fabre Pharmaceuticals holds the BLA and is working on resubmission with an updated dataset. Atara is eligible to receive milestone payments and tiered royalties under a global commercialization agreement with Pierre Fabre Laboratories. The company trades on Nasdaq under the ticker ATRA. Updated
On Tuesday, Canaccord Genuity reiterated its rating on Atara Biotherapeutics and raised its wildly bullish target price even higher.
Jon C. Ogg Atara Biotherapeutics finds itself caught between a rock and a hard place after Friday's drug study news concerning its treatment for multiple sclerosis.
Jon C. Ogg Atara Biotherapeutics is a T-cell immunotherapy company leveraging its allogeneic Epstein-Barr virus (EBV) T-cell platform to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions.
The Wall Street consensus 12-month price target for ATRA is $13.67.